カリフォルニア州におけるB細胞リンパ腫の臨床試験
カリフォルニア州内の拠点で、B細胞リンパ腫に関する20件の研究が参加者を募集しています。
カリフォルニア州内の都市
公式研究テキスト（英語）
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- University of California, Davis, Sacramento
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06343311A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Ucsf Fresno, Fresno
- Kaiser Permanente Southern California, Irvine
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06742996A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
- Providence Medical Foundation, Fullerton
- Cancer and Blood Specialty Clinic, Los Alamitos, Los Alamitos
- UCLA, Santa Monica
- 他1件
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07439653Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
- City of Hope Medical Center, Duarte
- City of Hope at Irvine Lennar, Irvine
被験者募集中第2相
60歳以上 · 全性別 · 2026/09/25更新 · NCT06052826A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- City of Hope, Duarte
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07101328Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Duarte
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06526793A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- University of Southern California Norris Comprehensive, Los Angeles
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06634589Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
- City of Hope Comprehensive Cancer Center, Duarte
- University of California Davis Comprehensive Cancer Center, Sacramento
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT05272384A Study of ARC-02 in B-cell NHL
- Start Cala, Los Angeles
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/26更新 · NCT07691606Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- University of California-Irvine Medical Center, Irvine
- Cedars-Sinai Medical Center, Los Angeles
- University of California, Los Angeles (UCLA) Medical Center, Los Angeles
- 他1件
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT05826535A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Pacific Cancer Medical Center, Inc, Anaheim
- TOI Clinical Research, Cerritos
- Stanford School of Medicine-Cancer Clinical Trials Office, Palo Alto
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05254743A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- City of Hope, Duarte
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/17更新 · NCT06528301A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Cedars-Sinai Medical Center, Los Angeles
- University of California, Los Angeles (UCLA), Los Angeles
- University of California, Irvine, Orange
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/04更新 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- UC San Diego Health, La Jolla
- Stanford University, Stanford
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/13更新 · NCT04792489Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
- Stanford Medical Center, Stanford
被験者募集中第2相
15歳以上 · 全性別 · 2026/05/27更新 · NCT06954805The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- City of Hope, Duarte
- Los Angeles Cancer Network, Los Angeles
- UCLA Medical Center of Hematology/Oncology, Los Angeles
- 他1件
被験者募集中第1/2相
12歳〜95歳 · 全性別 · 2026/04/15更新 · NCT04329728Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma
- City of Hope Medical Center, Duarte
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/05更新 · NCT05801913Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
- City of Hope Medical Center, Duarte
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/23更新 · NCT05432635BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
- City of Hope Medical Center, Duarte
- Stanford University, Stanford
被験者募集中第1相
18歳以上 · 全性別 · 2025/11/20更新 · NCT05370430Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital Los Angeles, Los Angeles
- Children's Hospital Orange County, Orange
- UCSF School of Medicine, San Francisco
被験者募集中第1相
1歳〜21歳 · 全性別 · 2024/12/06更新 · NCT05476770ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。